Objective: Tumor-stroma ratio (TSR) is a promising parameter representing the abundance of the stroma which has been validated in many solid tumors. However, it is still not clear which part of stroma mainly contribute to the prognostic value of TSR. The aim of this study is to confirm the prognostic value of TSR in a large cohort of oral squamous cell carcinoma (OSCC) and further demonstrated that cancer-associated fibroblasts (CAFs)-stroma ratio (CSR) contributed to the prognostic value of TSR.
Materials And Methods: TSR was evaluated on hematoxylin and eosin stained tissue samples from 581 patients with OSCC, which divides patients into high (>50%) and low (<50%) stroma. Then, CSR was estimated on immunohistochemical staining slides of 100 patients selected from 581 patients.
Results: In multivariate analysis, TSR was identified as an independent prognostic factor for disease-free survival (DFS) (p < 0.001) and oral cancer-specific survival (OCSS) (p < 0.001). The interaction term reached statistical significance for histological grade for DFS and OCSS separately. Furthermore, the high-stroma group had a higher CSR than the low-stroma group.
Conclusion: The prognostic value of TSR is validated in OSCC particularly in moderate and high differentiation, and CSR plays its part in the prognosis of TSR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/odi.14203 | DOI Listing |
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan430060, China.
To investigate the prognostic value of deep learning-based automated quantification of tumor-stroma ratio (TSR) in patients undergoing neoadjuvant therapy (NAT) for breast cancer. Specimens were collected from 209 breast cancer patients who received NAT at Renmin Hospital of Wuhan University from October 2019 to June 2023. TSR levels in pre-NAT biopsy specimens were automatically computed using a deep learning algorithm and categorized into low stroma (TSR≤30%), intermediate stroma (TSR 30% to ≤60%), and high stroma (TSR>60%) groups.
View Article and Find Full Text PDFEJNMMI Res
December 2024
Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Centre Rotterdam, Rotterdam, GD, 3015, The Netherlands.
Background: Fibroblast activation protein (FAP) is an attractive target for cancer theranostics. Although FAP-targeted nuclear imaging demonstrated promising clinical results, only sub-optimal results are reported for targeted radionuclide therapy (TRT). Preclinical research is crucial in selecting promising FAP-targeted radiopharmaceuticals and for obtaining an increased understanding of factors essential for FAP-TRT improvement.
View Article and Find Full Text PDFCancer Imaging
December 2024
Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany.
Background: The complex interactions of the tumor micromilieu may be reflected by diffusion-weighted imaging (DWI) derived from the magnetic resonance imaging (MRI). The present study investigated the association between apparent diffusion coefficient (ADC) values and histopathologic features in uterine cervical cancer.
Methods: In this retrospective study, prebiopsy MRI was used to analyze histogram ADC-parameters.
BMC Cancer
December 2024
Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, Turku, 20520, Finland.
Clin Nutr ESPEN
December 2024
Department of Surgery, Section Surgical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address:
Background & Aims: Sarcopenia and obesity are indicators for poor outcomes in colon cancer. Additionally, aggressive histopathologic tumor stromal features, such as a low tumor-stroma ratio (TSR) and low tumor-infiltrating lymphocytes (TILs) predict survival and treatment response. As their relationship remains underexplored, we studied the association between skeletal muscle mass, visceral adipose tissue (VAT), TSR, and TILs in patients with colon cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!